Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: A retrospective clinical study

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Satoh, Minoru ^a   Krzyszczak, Malgorzata E ^a   Li, Yi ^a   Ceribelli, Angela ^b   Ross, Steven J ^a,b   Chan, Edward K L ^b   Segal, Mark S ^a   Bubb, Michael R ^a   Sobel, Eric S ^a   Reeves, Westley H ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE KINASE; ENZYME ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RNA; TOPOISOMERASE I ANTIBODY; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; DNA TOPOISOMERASE; SMALL NUCLEAR RNA; U1 SMALL NUCLEAR RNA;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; POLYMYOSITIS; RACE DIFFERENCE; RADIOIMMUNOPRECIPITATION; RETROSPECTIVE STUDY; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; AGED; BLOOD; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED; SKIN DISEASE; SYSTEMIC SCLEROSIS;

ADULT; AFRICAN AMERICANS; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; DERMATOMYOSITIS; DNA TOPOISOMERASES, TYPE I; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, SMALL NUCLEAR; SCLERODERMA, SYSTEMIC; SEROEPIDEMIOLOGIC STUDIES; SEVERITY OF ILLNESS INDEX; SKIN DISEASES;

EID: 79955717511     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3334     Document Type: Article

References (35)

1. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994, 37:75-83. 10.1002/art.1780370111, 8129766.
2. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA, Wright TM. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999, 42:465-474. 10.1002/1529-0131(199904)42:3<465::AID-ANR11>3.0.CO;2-Y, 10088769.
3. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42. 10.1016/j.semarthrit.2005.03.005, 16084222.
4. Catoggio LJ, Bernstein RM, Black CM, Hughes GR, Maddison PJ. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983, 42:23-27. 10.1136/ard.42.1.23, 1001054, 6402991.
5. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 2003, 49:399-412. 10.1002/art.11113, 12794797.
6. Geisler C, Hoier-Madsen M. An enzyme-linked immunosorbent assay for autoantibodies against the nuclear protein Scl-70. J Immunol Methods 1985, 80:211-219. 10.1016/0022-1759(85)90022-5, 3925022.
7. al-Mekaimi A, Malaviya AN, Serebour F, Umamaheswaran I, Kumar R, al-Saeid K, Sharma PN. Serological characteristics of systemic lupus erythematosus from a hospital-based rheumatology clinic in Kuwait. Lupus 1997, 6:668-674. 10.1177/096120339700600808, 9364426.
8. Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:376-383. 10.1002/1529-0131(200102)44:2<376::AID-ANR56>3.0.CO;2-2, 11229469.
9. Hamidou MA, Audrain MA, Masseau A, Agard C, Moreau A. Anti-topoisomerase I antibodies in systemic lupus erythematosus as a marker of severe nephritis. Clin Rheumatol 2006, 25:542-543. 10.1007/s10067-005-0061-9, 16525896.
10. Satoh M, Chan EKL, Sobel ES, Kimpel DL, Yamasaki Y, Narain S, Mansoor R, Reeves WH. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol 2007, 3:721-738. 10.1586/1744666X.3.5.721, 20477023.
11. Mahler M, Silverman ED, Schulte-Pelkum J, Fritzler MJ. Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?. Autoimmun Rev 2010, 9:756-760. 10.1016/j.autrev.2010.06.005, 20601198, 20601198 .
12. Steen VD. The many faces of scleroderma. Rheum Dis Clin North Am 2008, 34:1-15. 10.1016/j.rdc.2007.12.001, 18329529.
13. Katsumi S, Kobayashi N, Yamamoto Y, Miyagawa S, Shirai T. Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody. Br J Dermatol 2000, 142:1030-1033. 10.1046/j.1365-2133.2000.03492.x, 10809868.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725.
16. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590. 10.1002/art.1780230510, 7378088, Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TAJ, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
18. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61:554-558. 10.1136/ard.61.6.554, 1754137, 12006334.
19. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347. 10.1056/NEJM197502132920706, 1090839.
20. Sharp GC. MCTD: a concept which stood the test of time. Lupus 2002, 11:333-339. 10.1191/0961203302lu220oa, 12139370.
21. Satoh M, Ajmani AK, Ogasawara T, Langdon JJ, Hirakata M, Wang J, Reeves WH. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome: specific recognition of the phosphorylated (IIO) form by a subset of human sera. J Clin Invest 1994, 94:1981-1989. 10.1172/JCI117550, 294621, 7962544.
22. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, Barros R, Santos MJ, Sousa E, Barcelos A, Ines L. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol 2009, 28:915-921. 10.1007/s10067-009-1175-2, 19390908.
23. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. 10.1056/NEJMoa021933, 14561795.
24. Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S, Kawano S, Kumagai S. Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol 2008, 18:153-60. 10.1007/s10165-008-0028-1, 18283522.
25. Tsay GJ, Fann RH, Hwang J. Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus. J Rheumatol 1990, 17:1314-1319.
26. Yamasaki Y, Narain S, Hernandez L, Barker T, Ikeda K, Segal MS, Richards HB, Chan EK, Reeves WH, Satoh M. Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res Ther 2006, 8:R111-R120. 10.1186/ar2000, 1779422, 16846524.
27. Kameda H, Kuwana M, Hama N, Kaburaki J, Homma M. Coexistence of serum anti-DNA topoisomerase I and anti-Sm antibodies: report of 3 cases. J Rheumatol 1997, 24:400-403.
28. Mukai S, Sagawa A, Atsumi T, Jodo S, Amasaki Y, Nakabayashi T, Watanabe I, Fujisaku A, Nakagawa S. Three cases of anti-Scl-70 (topoisomerase I) antibody associated with central nervous system lupus without renal disorder. J Rheumatol 1993, 20:1594-1597.
29. Sato S, Ihn H, Soma Y, Shimozuma M, Shishiba T, Takehara K. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies. J Rheumatol 1993, 20:1961-1963.
30. Hietarinta M, Lassila O, Hietaharju A. Association of anti-U1RNP-and anti-Scl-70-antibodies with neurological manifestations in systemic sclerosis (scleroderma). Scand J Rheumatol 1994, 23:64-67. 10.3109/03009749409103029, 8165439.
31. Cruz M, Mejia G, Lavalle C, Cortes JJ, Reyes PA. Antinuclear antibodies in scleroderma, mixed connective tissue disease and "primary" Raynaud's phenomenon. Clin Rheumatol 1988, 7:80-86. 10.1007/BF02284061, 3261675.
32. Okano Y, Medsger TA. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990, 33:1822-1828. 10.1002/art.1780331210, 1701994.
33. Okano Y, Steen VD, Medsger TAJ. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992, 35:95-100. 10.1002/art.1780350114, 1731817.
34. Steen VD, Ziegler GL, Rodnan GP, Medsger TA. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum 1984, 27:125-131. 10.1002/art.1780270202, 6607734.
35. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15:202-205.